As GLP-1 receptors are widely distributed in the central nervous system and GLP-1 RAs can cross the blood–brain barrier, the aforementioned benefits of GLP-1 RAs could have significant neuroprotective effects [127] and could account for the 24% relative risk reduction in nonfatal stroke (HR 0.76; 95% CI, 0.61–0.95), a prespecified secondary outcome in the REWIND trial (dulaglutide) [128], and for the 39% (HR 0.61; 95% CI, 0.38–0.99) for nonfatal stroke in the SUSTAIN-6 trial (semaglutide) [111]. The gene discussed is GLP1R; the disease is stroke disorder.